State Street Corp Buys 208,344 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS)

State Street Corp grew its position in Pyxis Oncology, Inc. (NASDAQ:PYXS) by 28.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 951,251 shares of the company’s stock after purchasing an additional 208,344 shares during the period. State Street Corp owned about 1.60% of Pyxis Oncology worth $3,491,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the company. Bank of New York Mellon Corp boosted its holdings in shares of Pyxis Oncology by 92.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 311,630 shares of the company’s stock worth $1,031,000 after buying an additional 149,522 shares during the last quarter. Rhumbline Advisers bought a new stake in Pyxis Oncology during the 2nd quarter worth approximately $216,000. Pier 88 Investment Partners LLC increased its holdings in shares of Pyxis Oncology by 121.4% in the second quarter. Pier 88 Investment Partners LLC now owns 113,700 shares of the company’s stock worth $376,000 after purchasing an additional 62,340 shares during the period. American Century Companies Inc. raised its holdings in shares of Pyxis Oncology by 56.0% in the 2nd quarter. American Century Companies Inc. now owns 58,252 shares of the company’s stock valued at $193,000 after acquiring an additional 20,901 shares in the last quarter. Finally, Schulhoff & Co. Inc. lifted its position in Pyxis Oncology by 90.9% during the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock valued at $139,000 after purchasing an additional 20,000 shares during the last quarter. Institutional investors own 39.09% of the company’s stock.

Insider Buying and Selling at Pyxis Oncology

In other news, CFO Pamela Ann Connealy purchased 88,850 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were purchased at an average cost of $1.96 per share, for a total transaction of $174,146.00. Following the purchase, the chief financial officer now directly owns 1,199,143 shares in the company, valued at approximately $2,350,320.28. This represents a 8.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 9.80% of the company’s stock.

Pyxis Oncology Price Performance

Shares of NASDAQ:PYXS opened at $1.56 on Tuesday. Pyxis Oncology, Inc. has a 1 year low of $1.49 and a 1 year high of $6.85. The stock’s fifty day moving average price is $2.76 and its 200-day moving average price is $3.22. The company has a market cap of $92.77 million, a P/E ratio of -1.51 and a beta of 1.00.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on PYXS. William Blair lowered Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. Stephens started coverage on Pyxis Oncology in a research report on Friday, November 8th. They issued an “overweight” rating and a $13.00 price objective on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $8.00 price objective (down from $10.00) on shares of Pyxis Oncology in a report on Friday, December 20th. Finally, HC Wainwright restated a “buy” rating and set a $5.00 target price (down previously from $7.00) on shares of Pyxis Oncology in a report on Friday, December 20th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Pyxis Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $9.43.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.